Please assess the completion status of the following clinical trial:

Trial Title: Mixed Incontinence: Medical Or Surgical Approach?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Female~2. Mixed UI as evidenced by stress and urge symptoms reported on MESA (either percent of urge-type symptoms ≥ the percent of stress-type symptoms or urge symptom score ≥7 if stress predominant) followed by report of moderately or greatly/quite a bit bothered to questions 2 and 3 of the 6-item Urinary Distress Index (UDI-6) or questions 16 and 17 of the 20-item Pelvic Fl;oor Distress Index (PFDI-20), respectively (See Appendix C)~3. Moderate or severe UI as evidenced by the corresponding response on the Patient Global Impression of Severity (PGI-S)~4. Incontinence symptoms present for at least (3) months\*~5. Bladder capacity \> 200cc (by any method)~6. Urodynamic Stress Incontinence~7. Eligible for both treatment interventions~8. Available to start intervention within 6 weeks~9. Negative urine dipstick (negative result = trace or less for leukocytes \& nitrites)~10. Available for 12 months of follow-up and able to complete study assessments as per clinician judgment~11. Signed consent form~Exclusion Criteria:~1. Age \<21 years\*~2. Currently undergoing or recommended to undergo treatment of pelvic organ prolapse~3. Other indicated/planned concomitant surgery~4. Pregnant or has not completed child bearing\*~5. \<12 months post-partum\*†~6. Active malignancy of cervix, uterus, fallopian tube(s) or ovary \> Stage I, or bladder of any Stage~7. Current catheter use~8. Unevaluated hematuria~9. Participation in another trial that may influence the results of this study~   * Patient can be rescreened after respective time interval has been met. †Partum is defined as a delivery or other termination that occurs after 20 weeks gestation.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Surgical Treatment (Type: ACTIVE_COMPARATOR): Surgical treatment will consist of the following evidence-based stress incontinence procedures: mid-urethral slings (TVT, TOT, TVT-O), fascial slings, and Burch colposuspension.
- Non Surgical Treatment (Type: ACTIVE_COMPARATOR): The non-surgical treatment will include two components:~1. Pharmacological therapy with any FDA approved overactive bladder (OAB) drug in approved doses; and~2. Behavioral therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).